VYNE Therapeutics (VYNE) Share-based Compensation Growth (3y) (2020 - 2026)
VYNE Therapeutics (VYNE) Share-based Compensation Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -50.27% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -17.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.88% |
| Jun 30, 2025 | 4.83% |
| Mar 31, 2025 | -5.11% |
| Dec 31, 2024 | 67.03% |
| Sep 30, 2024 | 29.56% |
| Jun 30, 2024 | -22.50% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -8.19% |
| Sep 30, 2023 | -55.77% |
| Jun 30, 2023 | 108.50% |
| Mar 31, 2023 | 43.95% |
| Dec 31, 2022 | 3.32% |
| Sep 30, 2022 | 29.61% |
| Jun 30, 2022 | -41.19% |
| Mar 31, 2022 | -2.04% |
| Dec 31, 2021 | 27.21% |
| Sep 30, 2021 | -83.95% |
| Jun 30, 2021 | 36.59% |
| Mar 31, 2021 | 43.76% |
| Dec 31, 2020 | -61.73% |